TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

David Bowen(University of Dundee), Michael J. Groves(University of Dundee), Alan K. Burnett(Cardiff University), Yashma Patel(University College London), Christopher Allen(University College London), C Green(University College London), Rosemary E. Gale(University College London), Robert K. Hills(Cardiff University), David C. Linch(University College London)

Leukemia

July 3, 2008

10.1038/leu.2008.173

Cited by 208

Abstract

Related Papers

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

Rosemary E. Gale, Claire Green, Christopher Allen et al.|Blood|2007|742

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Krzysztof Mrózek, Guido Marcucci, Peter Paschka et al.|Blood|2006|550

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Jan J. Cornelissen, Wim L.J. van Putten, Leo F. Verdonck et al.|Blood|2007|470

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

Anthony H. Goldstone, Alan K. Burnett, Keith Wheatley et al.|Blood|2001|436

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia

Adam J. Mead, David C. Linch, Robert K. Hills et al.|Blood|2007|322